Repressing HIF-1α-induced HDAC9 contributes to the synergistic effect of venetoclax and MENIN inhibitor in KMT2Ar AML

KMT2A-rearranged acute myeloid leukemia (KMT2Ar-AML) is an aggressive subtype of AML with poor response and prognosis. KMT2Ar-AML has been demonstrated to be sensitive to BCL2 inhibitor venetoclax (VEN), but these patients are unable to benefit from current VEN-based regimen (VEN plus azacitidine or...

Descripción completa

Detalles Bibliográficos
Autores principales: Ling, Qing, Zhou, Yutong, Qian, Yu, Qian, Jiejing, Zhang, Yi, Wang, Jinghan, Zhu, Yanan, Zhou, Yile, Wei, Juying, Yang, Chunmei, Sun, Jie, Yu, Wenjuan, Jin, Jie, Zhang, Xiang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Correspondence
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10696732/
http://dx.doi.org/10.1186/s40364-023-00547-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10696732/
http://dx.doi.org/10.1186/s40364-023-00547-9

Ejemplares similares